Evidence map›Paper›PMID 28925402›Full record

ArticleOncogene2018

Contrasting effects of an Mdm2 functional polymorphism on tumor phenotypes.

G J Ortiz, Y Li, S M Post, V Pant, S Xiong, C A Larsson, A K El-Naggar, D G Johnson, G Lozano

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncogene, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 17 citations in OpenAlex.

  1. Trial
  2. TP53 mutations and MDM2 polymorphisms in breast and ovarian cancers: amelioration by drugs and natural compounds.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Daxx Functions Are p53-IndependentMolecular cancer research : MCR · 2018
    Article
  10. SNPing away at mutant p53 activities.Genes & development · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

G J OrtizDepartment of Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Y LiDepartment of Epigenetics and Molecular Carcinogenesis at The Virginia Harris Cockrell Cancer Research Center, The University of Texas MD Anderson Cancer Center, Smithville, TX, USA.
S M PostDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
V PantDepartment of Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
S XiongDepartment of Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
C A LarssonDepartment of Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
A K El-NaggarDepartment of Pathology, Division of Pathology/Lab Medicine - Unit 085, The University of Texas MD Anderson Cancer, Houston, TX, USA.
D G JohnsonThe University of Texas Graduate School of Biomedical Sciences at Houston, Houston, TX, USA.
G LozanoDepartment of Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
The University of Texas MD Anderson Cancer Center · USCancer Research Center · USUniversity of Houston · US

Funding

PATHWAY OF TUMOR SUPPRESSIONR01CA047296 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI GUILLERMINA LOZANO · 1993 to 2026
$8.0M
Humanized Mouse Models for the p53 R72P SNPR01ES015587 · NIEHS · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI JOHNSON, DAVID G. · 2009 to 2013
$2.2M
NCI NIH HHS R01 CA047296NIEHS NIH HHS R01 ES015587
6 · The paper itself

Abstract

MDM2, an E3 ubiquitin ligase, is a potent inhibitor of the p53 tumor suppressor and is elevated in many human cancers that retain wild-type p53. MDM2 SNP309G is a functional polymorphism that results in elevated levels of MDM2 (due to enhanced SP1 binding to the MDM2 promoter) thus decreasing p53 activity. Mdm2

Indexed as

Genetic Predisposition to DiseaseAllelesAnimalsCarcinogensCarcinoma, Squamous CellDisease-Free SurvivalE2F6 Transcription FactorFemaleKeratinocytesMaleMiceMice, Inbred C57BLNeoplasms, ExperimentalPhenotypePolymorphism, Single NucleotidePrimary Cell CultureCarcinogensE2f6 protein, mouseE2F6 Transcription FactorMdm2 protein, mouseProto-Oncogene Proteins c-mdm2

Identifiers

PMID28925402
PMCPMC5775049
OpenAlexW2755529535

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.